SCHEMBL2944827

SCHEMBL2944827

Oc1ccc2cc(-c3cnc(-c4cn(Cc5ccccc5)c5ccccc45)o3)ccc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 2/20 0.48
SIRT2 Q8IXJ6 1/20 0.43
PTPN1 P18031 2/20 0.42
ESR1 P03372 2/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
F2RL3 Q96RI0 1/20 0.40
HSD17B1 P14061 1/20 0.39
HSD17B2 P37059 1/20 0.39
KCNH2 Q12809 1/20 0.39
DYRK1A Q13627 1/20 0.39
PLA2G2A P14555 1/20 0.39
BACE1 P56817 1/20 0.38
EGFR P00533 1/20 0.38
MET P08581 1/20 0.38
LMNA P02545 1/20 0.38
CYP19A1 P11511 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2946384 0.87 SIRT2 (0.44) ENPP2SIRT2ESR1CA12CA1
SCHEMBL2943810 0.85 THRA (0.44) ENPP2SIRT2PTPN1CA12CA1
SCHEMBL2945759 0.83 SIRT2 (0.39) ENPP2SIRT2PTPN1ESR1CA12
SCHEMBL2941621 0.83 KDM4E (0.46) HSD17B1HSD17B2
SCHEMBL2945320 0.82 PPARG (0.46) PTPN1F2RL3
SCHEMBL2945245 0.81 PTPN1 (0.38) ENPP2SIRT2PTPN1ESR1CA12
SCHEMBL2951909 0.80 F2RL3 (0.42) ENPP2SIRT2PTPN1CA12CA1
SCHEMBL2944855 0.75 LMNA (0.41) F2RL3LMNA
SCHEMBL2943298 0.74 ALOX15 (0.63) PTPN1ESR1HSD17B1HSD17B2LMNA
SCHEMBL2943242 0.71 ESR2 (0.47) PTPN1ESR1HSD17B1HSD17B2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754747-B2 Oxazolo-naphthyl acids WYETH LLC (US) 2010-07-13 US disclosed
EP-1781645-A1 OXAZOLO-NAPHTHYL ACIDS AS PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1(PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES Wyeth (US) 2007-05-09 EP disclosed
US-20060052348-A1 Oxazolo-naphthyl acids WYETH (US) 2006-03-09 US disclosed
WO-2006023865-A1 OXAZOLO-NAPHTHYL ACIDS AS PLAMINOGEN ACTIVATOR INHIBTOR TYPE-1 (PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES WYETH (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052348-A1 Oxazolo-naphthyl acids SERPINE1, SERPINB1, SERPINC1 ENPP2 135/4885SIRT2 1468/4885PTPN1 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.